<DOC>
	<DOCNO>NCT02346747</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , Phase 3 study maintenance Vigil Ovarian ( gemogenovatucel-T ) woman Stages IIIb , IIIc IV high-grade papillary serous/clear cell/endometrioid ovarian , fallopian tube primary peritoneal cancer . Subjects minimum 4 maximum 12 dos Vigil prepare stored ovarian tumor cell obtain time primary surgical debulking initial diagnostic/evaluative laparoscopy ( tissue immunotherapy manufacture must procure prior initiation neoadjuvant chemotherapy ) . An equal number placebo dos manufacture . Subjects achieve clinically defined complete response follow primary surgery adjuvant chemotherapy .</brief_summary>
	<brief_title>Phase 3 Trial Maintenance Vigil High Risk Stage IIIb-IV Ovarian Cancer</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , Phase 3 study maintenance Vigil Ovarian ( gemogenovatucel-T ) engineer autologous tumor cell ( EATC ) woman Stage IIIb , IIIc IV high-grade papillary serous/ clear cell / endometrioid ovarian , fallopian tube primary peritoneal cancer . Subjects minimum 4 maximum 12 dos Vigil prepare stored ovarian tumor cell obtain time primary surgical debulking initial diagnostic / evaluative laparoscopy ( tissue immunotherapy manufacture must procure prior initiation neoadjuvant chemotherapy ) . An equal number placebo dos manufacture . Subjects achieve clinically defined complete response follow primary surgery adjuvant chemotherapy . Investigational treatment must start less 3 week 8 week follow completion chemotherapy . Approximately 222 subject randomize 1:1 receive either monthly intradermal Vigil placebo least 4 maximum 12 administration . Randomization stratify ( ) extent surgical cytoreduction ( complete/microscopic versus macroscopic residual disease ) ( ii ) neoadjuvant versus adjuvant chemotherapy . The primary objective determine RFS subject randomize Vigil versus placebo , key secondary objective overall survival ( OS ) subject randomize Vigil versus placebo .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible tissue procurement Vigil manufacturing process meet follow criterion : 1 . Presumptive Stage IIIb , IIIc IV highgrade papillary serous/clear cell/endometrioid ovarian , fallopian tube primary peritoneal cancer . 2 . No chemotherapy prior investigational agent prior tissue acquisition Vigil manufacture . 3 . No malignancy ( exclude surgically cure nonmelanoma carcinoma skin carcinoma situ cervix ) unless remission ≥ 2 year . 4 . Anticipated availability cumulative mass ~30 gram tissue ( `` golfball '' size approximately 3cm disease CT scan ) time diagnostic laparoscopy primary surgical debulking . Infiltrating lumen ( bowel , fallopian tube , urethra ) tissue use Vigil immunotherapy material minimize risk bacterial contamination . 5 . ECOG performance status ( PS ) 02 prior diagnostic laparoscopy debulking laparotomy . 6 . No prior history hypersensitivity reaction ( HSR ) taxanes platinum . 7 . No prior history allergy sensitivities gentamicin . 8 . Female , 18 year age old . 9 . Ability understand willingness sign write informed consent document tissue harvest . Subjects register study meet follow inclusion criterion : 1 . Histologically confirm Stage IIIb , IIIc IV highgrade papillary serous/clear cell/endometrioid ovarian , fallopian tube primary peritoneal . 2 . Completion primary surgical debulking include hysterectomy bilateral salpingo oophorectomy , least 5 8 cycle platinum / taxane adjuvant chemotherapy chemotherapy per Category 1 recommendation NCCN guideline , include 58 cycle adjuvant intraperitoneal + intravenous ( IP/IV ) chemotherapy , 58 cycle intravenous chemotherapy divide administer neoadjuvant adjuvant therapy flank primary debulking surgery . 3 . Clinically define complete response ( cCR ) follow completion primary surgical debulking eligible chemotherapy . cCR define evidence malignancy chest xray ( CT scan acceptable ) CT scan MRI abdomen pelvis , normal physical examination , CA125 antigen level ≤ 35 U/ml ( assess ≥ 2 week follow removal catheter subject receive intraperitoneal/intravenous chemotherapy ) find physical examination symptom suggestive active cancer . 4 . Subjects must initiate adjuvant chemotherapy 8 week follow primary debulking surgery . 5 . Successful manufacturing least 4 dos ( vial ) Vigil placebo . 6 . Recovered clinically relevant toxicity relate prior therapy ( include neuropathy ≤Grade 2 ) . 7 . ECOG performance status ( PS ) 01 . 8 . Normal organ marrow function define : Absolute granulocyte count ≥ 1,500/mm^3 , Absolute lymphocyte count ≥ 500/mm^3 , Platelets ≥ 75,000/mm^3 , Total bilirubin ≤ 2 mg/dL , AST ( SGOT ) /ALT ( SGPT ) ≤ 2x institutional upper limit normal , Creatinine &lt; 1.5 mg/dL 9 . Ability understand willingness sign write inform protocol specific consent . Subjects exclude study meet follow criterion ( time tissue procurement randomization ) : 1 . Surgery involve general anesthesia , radiotherapy , immunotherapy , investigational agent within 4 week prior randomization . 2 . Histologically confirm papillary serous adenocarcinoma uterus disease involve myometrium/endometrium . 3 . Systemic immunosuppressive therapy within 14 day randomization . 4 . Subjects require chronic steroid immunosuppressive regimen exclude except inhaled / intranasal steroid short term systemic steroid &lt; 30 day duration ≤0.25 mg/kg prednisoneequivalent per day allow . 5 . Congestive heart failure ( NYHA Class II , III , IV ) , unstable angina , ventricular hemodynamically significant atrial arrhythmia , cardiovascular disease stroke myocardial infarction ( current within past 6 month ) . 6 . Psychiatric illness/social situation would limit compliance study requirement . 7 . Subjects history brain metastasis . 8 . Subjects know HIV chronic Hepatitis B C infection . 9 . Prior solid organ bone marrow transplant . 10 . History active autoimmune disease ( e.g. , autoimmune neutropenia , thrombocytopenia , hemolytic anemia , systemic lupus erythematosus , Sjogren 's syndrome , scleroderma , myasthenia gravis , Goodpasture 's syndrome , Addison 's disease , Hashimoto 's thyroiditis , Graves disease ) . Persons vitiligo exclude . Diabetics exclude condition well control .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage III</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Maintenance</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>endometrioid ovarian cancer</keyword>
	<keyword>high-grade serous ovarian cancer</keyword>
</DOC>